Mode
Text Size
Log in / Sign up

Cytokine release syndrome

Part of Systemic Inflammatory Response Syndrome

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for cytokine release syndrome

5 trials tracked for cytokine release syndrome.

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 5
  1. Phase 2 A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Completed
  2. Phase 2 A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Completed
  3. Phase 2 Efficacy and Safety of Itolizumab in COVID-19 Complications Completed
  4. Phase 2 Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Completed
  5. Phase 2 Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.